viewChemring Group

Chemring Group shares up as Barclays upgrades rating to ‘overweight’

Barclays has also increased its price target to 266p

In morning trading, Chemring Group’s shares rose 5.2% to 231.50p

Shares in defence contractor Chemring Group PLC (LON:CHG) jumped as Barclays upgraded its rating to ‘overweight’ from ‘equal weight’.

Barclays also increased its price target to 266p, as its move to a discounted cash flow (DCF) based valuation gives more credit for medium-term improvements.

READ: Chemring Group surges on back of improved showing from its Countermeasures division

In a note to clients, analysts at Barclays said they think that concern over the extent of end-market recovery and the level of major contract wins/losses overlooks the central tenet of the investments case: the self-help opportunity.

The analysts said: “Management is targeting 300basis point margin expansion on a like-for like basis by financial year 2022 versus financial year 2017 and we do not think this is fully in consensus.”

In morning trading, Chemring Group’s shares rose 5.2% to 231.50p.


Quick facts: Chemring Group

Price: 192.8 GBX

Market: LSE
Market Cap: £543.44 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...



Redx Pharma's chief scientific officer talks grant funding for its fibrosis...

Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...

15 minutes ago


Holding(s) in Company

1 week, 6 days ago

Total Voting Rights

2 weeks, 4 days ago

Total Voting Rights

on 1/10/19

2 min read